 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xenetic Biosciences, Inc. (XBIO) has disclosed a new risk, in the Share Price & Shareholder Rights category. Xenetic Biosciences, Inc. faces financ...

Xenetic Biosciences, Inc. Under Pressure: Shareholder Activism Threatens Stability and Financial Future

Xenetic Biosciences reports FY results...

Xenetic Biosciences reports FY results

Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumorsEnded the year with...

Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results

Xenetic Biosciences Inc (NASDAQ:XBIO  Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest...

Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Up 71.7% in January

- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platformFRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 / Xenetic Biosciences...

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.

Volume (M)	2,773.00
52-Wk High	$5.97
52-Wk Low	$2.55

XBIO Xenetic Biosciences Inc

About

Feed

News

Fundamentals